This page shows the latest asthma news and features for those working in and with pharma, biotech and healthcare.
It is estimated that around 176 million asthma exacerbations occur globally each year, which can prove fatal. ... growing body of evidence around the value of as-needed anti-inflammatory treatment in asthma and support PT027’s potential to transform
Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation. ... Dupixent significantly reduces asthma attacks, helps children breathe better and improves their health-related quality of life.”.
The data was presented at the 2022 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting and showed that patients treated with 300mg of Dupixent on a weekly basis experienced
of diseases, including dermatological diseases such as prurigo nodularis and atopic dermatitis, respiratory diseases such as asthma and CRSwNP, and gastrointestinal diseases such as eosinophilic esophagitis.”. ... Presently, Dupixent is approved in
Dupixent is already approved in the US, Europe, Japan and other countries for specific patient populations with atopic dermatitis and asthma.
maintenance treatment for adults and children aged 12 years and with severe asthma. ... The approval of Tezspire is long-awaited positive news for the asthma community.
More from news
Approximately 70 fully matching, plus 501 partially matching documents found.
In asthma it is down at around 50% and even in oncology the compliance figures are shocking.
Currently, we are developing MDT education in oncology, heart failure, diabetes, HIV and asthma.
From clinical research to the diagnosis and management of everything from asthma to oncology, we see opportunities at every contact point to improve the experience of people and communities who are
COPD. It has recently been approved by the FDA for asthma too, but our analysis focuses on UK performance.
Historically, asthma patients were responsible for recording their own symptoms and exacerbations, which can be difficult to remember over long periods. ... The Propeller platform has been shown to increase medication adherence by up to 58%, increase
More from intelligence
Approximately 3 fully matching, plus 51 partially matching documents found.
inflammation test for managing asthma, across key markets such as the United States, China, and Japan, as well as the rest of the world.
company's first respiratory biologic for severe asthma.
In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
Most recently these saw him serve as VP and medicines development leader responsible for the late-stage development of once-daily inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD).
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies
Boehringer Ingelheim recently introduced the first reusable, propellant-free inhaler for patients with asthma and COPD, supporting objectives of carbon and plastic waste reduction.
For example, with long term conditions such as asthma and diabetes, remote monitoring enables better self-management, which in turn, should lead to fewer hospital admissions, less face-to-face contact
This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma.
Asthma ads look like asthma ads because that's what the audience expects.
More from PMHub
Approximately 3 fully matching, plus 20 partially matching documents found.
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...